ARM Q2 2017 Quarterly Data Report

The Alliance for Regenerative Medicine's Q2 2017 Data Report details industry-specific statistics compiled from more than 822 cell therapy, gene therapy, tissue engineering and other regenerative medicine companies worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events and current legislative and regulatory priorities.

The Q2 2017 data report also features expert perspectives from ARM member representatives and other key stakeholders, highlighting important focus areas for the sector:

BlueRock Therapeutics:

  • Emile Nuwaysir, President & Chief Executive Officer

Cellular Dynamics International, a FUJIFILM company:

  • Lucas Chase, Director, Ocular Cell Therapy
  • Peter Fuhrken, Group Leader, Process Sciences
  • Derek Hei, Vice President, Clinical Manufacture, Quality and Regulatory
  • Amanda Mack, Director, iPSC Reprogramming
  • Christopher McMahon, Senior Group Leader

Addressing the unique aspects of market access and reimbursement policy for cell and gene therapies, with insights from:

  • Mark Trusheim, Visiting Scientist, MIT Sloan School of Management and Strategic Director, NEWDIGS, MIT Center for Biomedical Innovation

ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trial numbers and clinical data events.

To view and download previously released data reports and ARM presentations, please click here.

To download the report, please fill out the form below.

The report includes standalone graphics highlighting key data points, available below. Please right-click on the desired file type (.jpg or .png) to save the image to your computer.

 

[.jpg]   [.png]

[.jpg]   [.png]

[.jpg]   [.png]

[.jpg]   [.png]

[.jpg]   [.png]

SaveSave

SaveSave